Cerus (NASDAQ:CERS) Insider Chrystal Jensen Sells 30,000 Shares of Stock

Cerus Corporation (NASDAQ:CERS) insider Chrystal Jensen sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $2.98, for a total transaction of $89,400.00. Following the completion of the sale, the insider directly owned 936,657 shares in the company, valued at approximately $2,791,237.86. This trade represents a 3.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Chrystal Jensen also recently made the following trade(s):

• On Tuesday, June 30th, Chrystal Jensen sold 24,329 shares of Cerus stock. The shares were sold at an average price of $2.94, for a total transaction of $71,527.26.

Cerus Stock Down 0.3%

CERS opened at $2.97 on Tuesday. Cerus Corporation has a 12 month low of $1.15 and a 12 month high of $3.47. The company has a market cap of $598.51 million, a PE ratio of -99.00 and a beta of 1.81. The company has a current ratio of 1.83, a quick ratio of 1.07 and a debt-to-equity ratio of 0.49. The company has a 50 day moving average of $2.81 and a 200 day moving average of $2.43.

Cerus (NASDAQ:CERS) last issued its earnings results on Thursday, July 30th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01). The business had revenue of $63.30 million for the quarter, compared to analysts’ expectations of $62.90 million. Cerus had a negative net margin of 3.06% and a negative return on equity of 10.19%. On average, sell-side analysts expect that Cerus Corporation will post -0.04 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Bank of America Corp DE bought a new stake in Cerus during the second quarter valued at approximately $2,536,000. Hsbc Holdings PLC bought a new position in shares of Cerus in the 2nd quarter worth $277,000. Primecap Management Co. CA purchased a new stake in shares of Cerus during the 2nd quarter valued at $2,283,000. Legal & General Group Plc purchased a new stake in shares of Cerus during the 2nd quarter valued at $56,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Cerus during the 2nd quarter worth $160,000. 78.37% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cerus in a research note on Thursday, June 18th. Wall Street Zen cut Cerus from a “buy” rating to a “hold” rating in a research report on Saturday. BTIG Research raised shares of Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Friday, May 1st. Finally, Zacks Research upgraded shares of Cerus from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 30th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $4.00.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.